A Registry Study on the "Action of Controlling Ambulatory Blood Pressure to Target in Ten Thousand Patients"

NCT03547856 | Recruiting

• 1 other identifier: REACTION-ABP
• Study Type: observational
• Target: 10,000
• Locations: 1 country
• Sites: 1

Brief Summary

24 hour ambulatory blood pressure (ABP) monitoring should be the first choice for diagnosis and treatment of hypertension according to European Societyof Hypertension (ESH) and the European Society of Cardiology (ESC) guideline on ambulatory blood pressure monitoring. Finally, we should promote the clinical application of 24 hour ambulatory blood pressure monitoring to greatly improve the management level of hypertension in China and effectively reduce the risk caused by hypertension in the population. Information of hypertensive patients with ambulatory blood pressure monitoring was prospectively registered nationwide,and then to investigate whether there was difference in cardiovascular prognosis according to the control of ABP.

Conditions

Hypertension; Blood Pressure; Cardiovascular Diseases

Outcome Measures

Primary Outcomes (1)

• Composite end point of major cardiovascular and cerebrovascular events

  Composite end point of major cardiovascular and cerebrovascular events

  From date of enrollment until date of first documented event or date of death from cardiovascular and cerebrovascular events, whichever came first, assessed up to 3 years

Secondary Outcomes (5)

• The control rate of clinic blood pressure

  From date of enrollment until study completion,an average of 3 years

• The control rate of 24-hour ambulatory blood pressure

  From date of enrollment until study completion,an average of 3 years

• the proportion of white-coat uncontrolled hypertension

  From date of enrollment until study completion,an average of 3 years

• the proportion of masked uncontrolled hypertension

  From date of enrollment until study completion,an average of 3 years

• The occurrence time of cardiovascular events in different groups

  From date of enrollment until date of first documented event or date of death from cardiovascular and cerebrovascular events, whichever came first, assessed up to 3 years

Eligibility Criteria

• Age: 18 Years - 80 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

primary care clinic, and community sample

You may qualify if:

• Age 18-80 years old
• Clinical diagnosed hypertension with the use of antihypertensive drugs
• A 24-hour ambulatory blood pressure monitoring was performed with validated equipment.
• Willing to provide information about disease history and blood biochemical test data within 6 months.
• Sign the informed consent

You may not qualify if:

• Without antihypertensive drug use
• Hospitalized hypertension patients
• Non-compliant patient

Sponsors & Collaborators

• Yan Li: lead

Study Sites (1)

Ruijin Hospital

Shanghai, Shanghai Municipality, 200025, China

RECRUITING

MeSH Terms

Conditions

Hypertension; Cardiovascular Diseases

Condition Hierarchy (Ancestors)

Vascular Diseases

Study Officials

• Yan Li

  Shanghai Institute of Hypertension

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Yan Li, Professor

CONTACT

021-64370045; liyanshcn@yahoo.com

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: Professor of Cardiovascular Medicine

Study Record Dates

• First Submitted: May 2, 2018
• First Posted: June 6, 2018
• Study Start: July 18, 2018
• Primary Completion (Estimated): September 30, 2026
• Study Completion (Estimated): December 30, 2026
• Last Updated: January 6, 2025

Record last verified: 2025-01

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)